<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473524</url>
  </required_header>
  <id_info>
    <org_study_id>747-301</org_study_id>
    <nct_id>NCT01473524</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis</brief_title>
  <acronym>POISE</acronym>
  <official_title>A Phase 3, Double-Blind, Placebo-Controlled Trial and Long-Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on&#xD;
      serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on&#xD;
      safety in participants with primary biliary cirrhosis (PBC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study included 2 phases: a 12-month randomized, double-blind (DB), placebo-controlled,&#xD;
      parallel group phase, followed by a long-term safety extension (LTSE) phase up to 5 years.&#xD;
      Participants from the 12-month DB phase, including those who received placebo, were eligible&#xD;
      to participate in the open-label LTSE phase. The Month 12 visit from the DB phase served as&#xD;
      the Day 1 visit of the LTSE phase. After completion of the 12-month DB phase all participants&#xD;
      were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg&#xD;
      OCA.&#xD;
&#xD;
      Data for the LTSE phase is reported by the randomized dose group assigned in the DB phase.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 17, 2018</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo</measure>
    <time_frame>DB Month 12</time_frame>
    <description>Percentage of participants at Month 12 with ALP &lt; 1.67 x upper limit of normal (ULN) and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LTSE Phase: Composite Endpoint ALP And Total Bilirubin</measure>
    <time_frame>Baseline (DB Month 12), LTSE Months 24, 36, 48, and 60</time_frame>
    <description>Percentage of participants at Months 24, 36, 48, and 60 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. DB Month 12 is the baseline for the LTSE phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Composite Endpoint ALP And Total Bilirubin, 10 mg Versus Placebo</measure>
    <time_frame>DB Month 6</time_frame>
    <description>Percentage of participants at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo</measure>
    <time_frame>DB Month 12</time_frame>
    <description>Percentage of participants at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo</measure>
    <time_frame>DB Month 6</time_frame>
    <description>Percentage of participants at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: ALP Absolute Change From Baseline To Month 12</measure>
    <time_frame>Baseline, DB Month 12</time_frame>
    <description>Blood samples were evaluated for ALP levels. ALP Absolute Change From Baseline (ALP at Month 12 - ALP at Baseline) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Total Bilirubin Absolute Change From Baseline To Month 12</measure>
    <time_frame>Baseline, DB Month 12</time_frame>
    <description>Blood samples were evaluated for bilirubin levels. Total bilirubin absolute change from baseline (total bilirubin at Month 12 - total bilirubin at Baseline) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Direct Bilirubin Absolute Change From Baseline To Month 12</measure>
    <time_frame>Baseline, DB Month 12</time_frame>
    <description>Blood samples were evaluated for bilirubin levels. Direct bilirubin absolute change from baseline (direct bilirubin at Month 12 - direct bilirubin at Baseline) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Alanine Aminotransferase (ALT) Absolute Change From Baseline To Month 12</measure>
    <time_frame>Baseline, DB Month 12</time_frame>
    <description>Blood samples were evaluated for ALT levels. ALT absolute change from baseline (ALT at Month 12 - ALT at Baseline) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Aspartate Aminotransferase (AST) Absolute Change From Baseline To Month 12</measure>
    <time_frame>Baseline, DB Month 12</time_frame>
    <description>Blood samples were evaluated for AST levels. AST absolute change from baseline (AST at Month 12 - AST at Baseline) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DB Phase: Gamma-glutamyltransferase (GGT) Absolute Change From Baseline To Month 12</measure>
    <time_frame>Baseline, DB Month 12</time_frame>
    <description>Blood samples were evaluated for GGT levels. GGT absolute change from baseline (GGT at Month 12 - GGT at Baseline) is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTSE Phase: ALP Levels</measure>
    <time_frame>LTSE Day 0 and LTSE Months 12, 24, 36, 48, and 60</time_frame>
    <description>Blood samples were evaluated for ALP levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LTSE Phase: ALP Change From DB Baseline</measure>
    <time_frame>DB Baseline, LTSE Months 12, 24, 36, 48, and 60</time_frame>
    <description>Blood samples were evaluated for ALP levels. ALP Change From Baseline (ALP at LTSE Months 12, 24, 36, 48, and 60 - ALP at Baseline) is presented. DB baseline is the mean of all available evaluations prior to DB treatment.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>DB OCA 5-10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 5 milligram (mg) for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DB OCA 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 10 mg for 12 months during the DB phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DB Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for 12 months during the DB phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LTSE OCA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg. Participants who were previously titrated above 10 mg OCA daily were down-titrated to ≤10 mg OCA daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic Acid (OCA)</intervention_name>
    <description>OCA was administered orally once daily and provided in tablet form in 2 strengths: 5 mg and 10 mg.</description>
    <arm_group_label>DB OCA 10 mg</arm_group_label>
    <arm_group_label>DB OCA 5-10 mg</arm_group_label>
    <arm_group_label>LTSE OCA</arm_group_label>
    <other_name>6α-ethyl chenodeoxycholic acid (6-ECDCA)</other_name>
    <other_name>INT-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablets were administered orally once daily.</description>
    <arm_group_label>DB Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Definite or probable PBC diagnosis (consistent with American Association for the Study&#xD;
             of Liver Disease [AASLD] and European Association for Study of the Liver [EASL]&#xD;
             Practice Guidelines; [Lindor 2009; EASL 2009]), as demonstrated by the presence of ≥ 2&#xD;
             of the following 3 diagnostic factors:&#xD;
&#xD;
               -  History of elevated alkaline phosphatase (ALP) levels for at least 6 months&#xD;
&#xD;
               -  Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low&#xD;
                  titer (&lt;1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or&#xD;
                  antibodies against the major M2 components (pyruvate dehydrogenase complex-E2&#xD;
                  [PDC-E2], 2-oxo-glutaric acid dehydrogenase complex)&#xD;
&#xD;
               -  Liver biopsy consistent with PBC&#xD;
&#xD;
          2. At least 1 of the following qualifying biochemistry values:&#xD;
&#xD;
               -  ALP ≥ 1.67x upper limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin &gt; ULN but &lt; 2x ULN&#xD;
&#xD;
          3. Age ≥ 18 years&#xD;
&#xD;
          4. Taking ursodeoxycholic acid (UDCA) for at least 12 months (stable dose for ≥ 3 months)&#xD;
             prior to Day 0, or unable to tolerate UDCA (no UDCA for ≥ 3 months) prior to Day 0.&#xD;
&#xD;
          5. Contraception: Female participants must be postmenopausal, surgically sterile, or if&#xD;
             premenopausal, be prepared to use ≥ 1 effective (≤ 1% failure rate) method of&#xD;
             contraception during the trial and for 30 days after the end of treatment (EOT) visit.&#xD;
             Effective methods of contraception are considered to be:&#xD;
&#xD;
               -  Hormonal (for example, contraceptive pill, patch, intramuscular implant or&#xD;
                  injection); or&#xD;
&#xD;
               -  Double barrier method, that is, (a) condom (male or female) or (b) diaphragm,&#xD;
                  with spermicide; or&#xD;
&#xD;
               -  Intrauterine device (IUD); or&#xD;
&#xD;
               -  Vasectomy (partner); or&#xD;
&#xD;
               -  Sexual abstinence&#xD;
&#xD;
          6. Must provide written informed consent and agree to comply with the trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History or presence of other concomitant liver diseases including:&#xD;
&#xD;
               -  Hepatitis C virus (HCV) infection; participants with active hepatitis B (HBV)&#xD;
                  infection will be excluded, however, participants who have seroconverted&#xD;
                  (hepatitis B surface antigen [Hbs Ag] and hepatitis B e antigen [Hbe Ag]&#xD;
                  negative) may be included after consultation with the medical monitor.&#xD;
&#xD;
               -  Primary sclerosing cholangitis (PSC)&#xD;
&#xD;
               -  Alcoholic liver disease&#xD;
&#xD;
               -  Definite autoimmune liver disease or overlap hepatitis&#xD;
&#xD;
               -  Nonalcoholic steatohepatitis (NASH)&#xD;
&#xD;
               -  Gilbert's Syndrome (due to interpretability of bilirubin levels)&#xD;
&#xD;
          2. Presence of clinical complications of PBC or clinically significant hepatic&#xD;
             decompensation, including:&#xD;
&#xD;
               -  History of liver transplantation, current placement on a liver transplant list or&#xD;
                  current Model for End Stage Liver Disease (MELD) score ≥ 15&#xD;
&#xD;
               -  Portal hypertension with complications, including: known gastric or large&#xD;
                  esophageal varices, poorly controlled or diuretic resistant ascites, history of&#xD;
                  variceal bleeds or related therapeutic or prophylactic interventions (for&#xD;
                  example, beta blockers, insertion of variceal bands or transjugular intrahepatic&#xD;
                  portosystemic shunt [TIPS]), or hepatic encephalopathy&#xD;
&#xD;
               -  Cirrhosis with complications, including history or presence of: spontaneous&#xD;
                  bacterial peritonitis, hepatocellular carcinoma, bilirubin &gt; 2x ULN&#xD;
&#xD;
               -  Hepatorenal syndrome (type I or II) or Screening serum creatinine &gt; 2&#xD;
                  mg/deciliter dL) (178 micromole [µmol])/liter [L])&#xD;
&#xD;
          3. Participants with severe pruritus or those requiring systemic treatment for pruritus&#xD;
             (for example, with bile acid sequestrants [BAS] or rifampicin) within 2 months of Day&#xD;
             0 will be excluded&#xD;
&#xD;
          4. Administration of the following medications is prohibited as specified below:&#xD;
&#xD;
               -  Prohibited 6 months prior to Day 0 and throughout the trial (that is, to last&#xD;
                  dose and/or EOT): azathioprine, colchicine, cyclosporine, methotrexate,&#xD;
                  mycophenolate mofetil, pentoxifylline; fenofibrate or other fibrates; budesonide&#xD;
                  and other systemic corticosteroids; potentially hepatotoxic drugs (including&#xD;
                  α-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)&#xD;
&#xD;
               -  Prohibited 12 months prior to Day 0 and throughout the trial (that is, to last&#xD;
                  dose and/or EOT): antibodies or immunotherapy directed against interleukins or&#xD;
                  other cytokines or chemokines&#xD;
&#xD;
          5. Participants who have previously participated in a clinical trial of OCA will not be&#xD;
             allowed to participate&#xD;
&#xD;
          6. History or presence of clinically concerning cardiac arrhythmias likely to affect&#xD;
             survival during the trial, or prolongation of Screening (pretreatment) QT or QTc&#xD;
             interval of &gt; 500 milliseconds (msec)&#xD;
&#xD;
          7. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a&#xD;
             positive serum pregnancy test), or lactating&#xD;
&#xD;
          8. Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          9. Presence of any other disease or condition that is interfering with the absorption,&#xD;
             distribution, metabolism, or excretion of drugs including bile salt metabolism in the&#xD;
             intestine. Participants with inflammatory bowel disease or who have undergone gastric&#xD;
             bypass procedures will be excluded (gastric lap band is acceptable).&#xD;
&#xD;
         10. Medical conditions that may cause nonhepatic increases in ALP (for example, Paget's&#xD;
             disease) or which may diminish life expectancy to &lt; 2 years, including known cancers&#xD;
             (except carcinomas in situ or other stable, relatively benign conditions such as&#xD;
             chronic lymphatic leukemia)&#xD;
&#xD;
         11. Other clinically significant medical conditions that are not well controlled or for&#xD;
             which medication needs are anticipated to change during the trial&#xD;
&#xD;
         12. Anticipated changes to current concomitant medications during the course of the trial&#xD;
&#xD;
         13. History of alcohol abuse, defined as consumption of more than 210 mL of alcohol per&#xD;
             week (that is, the equivalent of fourteen 4-ounce (125 mL) glasses of wine or fourteen&#xD;
             12 ounce cans/bottles of beer), or other substance abuse within 1 year prior to Day 0&#xD;
&#xD;
         14. Participation in another investigational drug, biologic, or medical device trial&#xD;
             within 30 days prior to Screening&#xD;
&#xD;
         15. History of noncompliance with medical regimens, or participants who are considered to&#xD;
             be potentially unreliable&#xD;
&#xD;
         16. Blood or plasma donation within 30 days prior to Day 0&#xD;
&#xD;
         17. Mental instability or incompetence, such that the validity of informed consent or&#xD;
             compliance with the trial is uncertain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Weyer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Intercept Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hôpital St-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Alexander-Universität Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang Goethe Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis, Dres. Felten / Hartmann / Hüppe</name>
      <address>
        <city>Herne</city>
        <zip>D-44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. Medicina Clinica - Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. Medicina Clinica- Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova - Gastroenterologia</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUmc Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud, Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All-Medicus</name>
      <address>
        <city>Katowice</city>
        <zip>40-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Gastroenterologii i Hepatologii SP CSK im. prof. K. Gibinskiego SUM</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej &quot;SONOMED&quot;</name>
      <address>
        <city>Szczecin</city>
        <zip>70-361</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej - Curie, Klinika Gastroenterologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital Dundee</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forth Valley Royal Hospital</name>
      <address>
        <city>Larbert</city>
        <zip>FK5 4WR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cellular Medicine, Newcastle University</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE2 4 HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906.</citation>
    <PMID>19554543</PMID>
  </reference>
  <results_reference>
    <citation>Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.</citation>
    <PMID>27532829</PMID>
  </results_reference>
  <results_reference>
    <citation>Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, Andreone P, Hirschfield GM, Pencek R, Malecha ES, MacConell L, Shapiro D. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):445-453. doi: 10.1016/S2468-1253(19)30094-9. Epub 2019 Mar 26.</citation>
    <PMID>30922873</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <results_first_submitted>December 20, 2016</results_first_submitted>
  <results_first_submitted_qc>December 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2017</results_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <keyword>PBC</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment into hospitals and physicians' clinics started January 2012 and completed December 2012.</recruitment_details>
      <pre_assignment_details>Screening interim allowed for pre-randomization eligibility assessment of 1 to 8 weeks.&#xD;
A total of 217 participants were randomized into the double-blind phase of the study, however, 216 received treatment with study drug. One randomized participant discontinued prior to receiving any study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DB OCA 5-10 mg</title>
          <description>Obeticholic acid (OCA) 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the double-blind (DB) phase.</description>
        </group>
        <group group_id="P2">
          <title>DB OCA 10 mg</title>
          <description>OCA 10 mg for 12 months during DB phase.</description>
        </group>
        <group group_id="P3">
          <title>DB Placebo</title>
          <description>Matching placebo for 12 months in the DB phase.</description>
        </group>
        <group group_id="P4">
          <title>LTSE OCA (DB OCA 5-10 mg)</title>
          <description>Participants previously receiving OCA 5 to 10 mg in the DB phase received OCA in the open-label long-term safety extension (LTSE) phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="P5">
          <title>LTSE OCA (DB OCA 10 mg)</title>
          <description>Participants previously receiving OCA 10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="P6">
          <title>LTSE OCA (DB Placebo)</title>
          <description>Participants previously receiving placebo in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>DB Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>LTSE Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="63">One participant in the double-blind OCA 5-10 mg group did not enroll in the LTSE phase.</participants>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="66">Four participants in the double-blind placebo group did not enroll in the LTSE phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of OCA in LTSE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="64"/>
                <participants group_id="P6" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="54"/>
                <participants group_id="P5" count="47"/>
                <participants group_id="P6" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="17"/>
                <participants group_id="P6" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event of Pruritus</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Clinical/ Laboratory Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principal Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Liver Transplantation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>DB OCA 5-10 mg</title>
          <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.&#xD;
After completion of the 12-month DB phase participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="B2">
          <title>DB OCA 10 mg</title>
          <description>OCA 10 mg 12 months during the DB phase. After completion of the 12-month DB phase participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="B3">
          <title>DB Placebo</title>
          <description>Matching placebo for 12 months during the DB phase. After completion of the 12-month DB phase participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="10.53"/>
                    <measurement group_id="B2" value="56.2" spread="11.00"/>
                    <measurement group_id="B3" value="55.5" spread="10.03"/>
                    <measurement group_id="B4" value="55.8" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline Phosphatase (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325.87" spread="116.238"/>
                    <measurement group_id="B2" value="316.34" spread="103.881"/>
                    <measurement group_id="B3" value="327.49" spread="115.014"/>
                    <measurement group_id="B4" value="323.19" spread="111.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Bilirubin (umol/L)</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.192" spread="5.549"/>
                    <measurement group_id="B2" value="11.278" spread="6.634"/>
                    <measurement group_id="B3" value="11.757" spread="7.227"/>
                    <measurement group_id="B4" value="11.088" spread="6.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Direct Bilirubin (umol/L)</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.398" spread="4.528"/>
                    <measurement group_id="B2" value="4.868" spread="4.473"/>
                    <measurement group_id="B3" value="5.469" spread="6.214"/>
                    <measurement group_id="B4" value="4.919" spread="5.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine Aminotransferase (ALT) (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.56" spread="39.037"/>
                    <measurement group_id="B2" value="56.31" spread="39.741"/>
                    <measurement group_id="B3" value="55.99" spread="30.312"/>
                    <measurement group_id="B4" value="57.9" spread="36.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate Aminotransferase (AST) (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.25" spread="25.289"/>
                    <measurement group_id="B2" value="50.49" spread="31.100"/>
                    <measurement group_id="B3" value="48.79" spread="22.449"/>
                    <measurement group_id="B4" value="50.49" spread="26.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gamma-Glutamyltransferase (GGT) (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252.83" spread="167.038"/>
                    <measurement group_id="B2" value="261.07" spread="207.396"/>
                    <measurement group_id="B3" value="309.58" spread="449.356"/>
                    <measurement group_id="B4" value="274.79" spread="302.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo</title>
        <description>Percentage of participants at Month 12 with ALP &lt; 1.67 x upper limit of normal (ULN) and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Composite Endpoint Alkaline Phosphatase (ALP) And Total Bilirubin, 10 mg OCA Versus Placebo</title>
          <description>Percentage of participants at Month 12 with ALP &lt; 1.67 x upper limit of normal (ULN) and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 10 mg OCA. H1: The response rates are different between placebo and 10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>LTSE Phase: Composite Endpoint ALP And Total Bilirubin</title>
        <description>Percentage of participants at Months 24, 36, 48, and 60 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. DB Month 12 is the baseline for the LTSE phase.</description>
        <time_frame>Baseline (DB Month 12), LTSE Months 24, 36, 48, and 60</time_frame>
        <population>All participants who received at least 1 dose of OCA in the open-label safety extension phase and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>LTSE OCA (DB OCA 5-10 mg)</title>
            <description>Participants previously receiving OCA 5-10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O2">
            <title>LTSE OCA (DB OCA 10 mg)</title>
            <description>Participants previously receiving OCA 10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O3">
            <title>LTSE OCA (DB Placebo)</title>
            <description>Participants previously receiving placebo in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O4">
            <title>Overall LTSE OCA</title>
            <description>After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>LTSE Phase: Composite Endpoint ALP And Total Bilirubin</title>
          <description>Percentage of participants at Months 24, 36, 48, and 60 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline. DB Month 12 is the baseline for the LTSE phase.</description>
          <population>All participants who received at least 1 dose of OCA in the open-label safety extension phase and had an assessment at the specified timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Double-blind Month 12)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Composite Endpoint ALP And Total Bilirubin, 10 mg Versus Placebo</title>
        <description>Percentage of participants at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>DB Month 6</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Double-blind OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>Double-blind Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Composite Endpoint ALP And Total Bilirubin, 10 mg Versus Placebo</title>
          <description>Percentage of participants at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 10 mg OCA. H1: The response rates are different between placebo and 10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo</title>
        <description>Percentage of participants at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo</title>
          <description>Percentage of participants at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 5-10 mg OCA. H1: The response rates are different between placebo and 5-10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo</title>
        <description>Percentage of participants at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>DB Month 6</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Composite Endpoint ALP And Total Bilirubin, 5-10 mg Versus Placebo</title>
          <description>Percentage of participants at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 5-10 mg OCA. H1: The response rates are different between placebo and 5-10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: ALP Absolute Change From Baseline To Month 12</title>
        <description>Blood samples were evaluated for ALP levels. ALP Absolute Change From Baseline (ALP at Month 12 - ALP at Baseline) is presented.</description>
        <time_frame>Baseline, DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O3">
            <title>DB Placebo</title>
            <description>Matching placebo during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: ALP Absolute Change From Baseline To Month 12</title>
          <description>Blood samples were evaluated for ALP levels. ALP Absolute Change From Baseline (ALP at Month 12 - ALP at Baseline) is presented.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-112.51" spread="14.36"/>
                    <measurement group_id="O2" value="-129.90" spread="14.60"/>
                    <measurement group_id="O3" value="-14.42" spread="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Total Bilirubin Absolute Change From Baseline To Month 12</title>
        <description>Blood samples were evaluated for bilirubin levels. Total bilirubin absolute change from baseline (total bilirubin at Month 12 - total bilirubin at Baseline) is presented.</description>
        <time_frame>Baseline, DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O3">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Total Bilirubin Absolute Change From Baseline To Month 12</title>
          <description>Blood samples were evaluated for bilirubin levels. Total bilirubin absolute change from baseline (total bilirubin at Month 12 - total bilirubin at Baseline) is presented.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
          <units>umol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.68"/>
                    <measurement group_id="O2" value="-0.90" spread="0.71"/>
                    <measurement group_id="O3" value="1.98" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Direct Bilirubin Absolute Change From Baseline To Month 12</title>
        <description>Blood samples were evaluated for bilirubin levels. Direct bilirubin absolute change from baseline (direct bilirubin at Month 12 - direct bilirubin at Baseline) is presented.</description>
        <time_frame>Baseline, DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O3">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Direct Bilirubin Absolute Change From Baseline To Month 12</title>
          <description>Blood samples were evaluated for bilirubin levels. Direct bilirubin absolute change from baseline (direct bilirubin at Month 12 - direct bilirubin at Baseline) is presented.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
          <units>umol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.52"/>
                    <measurement group_id="O2" value="-0.49" spread="0.54"/>
                    <measurement group_id="O3" value="1.89" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Alanine Aminotransferase (ALT) Absolute Change From Baseline To Month 12</title>
        <description>Blood samples were evaluated for ALT levels. ALT absolute change from baseline (ALT at Month 12 - ALT at Baseline) is presented.</description>
        <time_frame>Baseline, DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O3">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Alanine Aminotransferase (ALT) Absolute Change From Baseline To Month 12</title>
          <description>Blood samples were evaluated for ALT levels. ALT absolute change from baseline (ALT at Month 12 - ALT at Baseline) is presented.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.26" spread="3.27"/>
                    <measurement group_id="O2" value="-25.31" spread="3.35"/>
                    <measurement group_id="O3" value="-4.95" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Aspartate Aminotransferase (AST) Absolute Change From Baseline To Month 12</title>
        <description>Blood samples were evaluated for AST levels. AST absolute change from baseline (AST at Month 12 - AST at Baseline) is presented.</description>
        <time_frame>Baseline, DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 12 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O3">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Aspartate Aminotransferase (AST) Absolute Change From Baseline To Month 12</title>
          <description>Blood samples were evaluated for AST levels. AST absolute change from baseline (AST at Month 12 - AST at Baseline) is presented.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.03" spread="4.17"/>
                    <measurement group_id="O2" value="-15.00" spread="4.28"/>
                    <measurement group_id="O3" value="1.04" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DB Phase: Gamma-glutamyltransferase (GGT) Absolute Change From Baseline To Month 12</title>
        <description>Blood samples were evaluated for GGT levels. GGT absolute change from baseline (GGT at Month 12 - GGT at Baseline) is presented.</description>
        <time_frame>Baseline, DB Month 12</time_frame>
        <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>DB OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
          </group>
          <group group_id="O2">
            <title>DB OCA 10 mg</title>
            <description>OCA 10 mg for 12 months during the DB phase.</description>
          </group>
          <group group_id="O3">
            <title>DB Placebo</title>
            <description>Matching placebo for 12 months during the DB phase.</description>
          </group>
        </group_list>
        <measure>
          <title>DB Phase: Gamma-glutamyltransferase (GGT) Absolute Change From Baseline To Month 12</title>
          <description>Blood samples were evaluated for GGT levels. GGT absolute change from baseline (GGT at Month 12 - GGT at Baseline) is presented.</description>
          <population>Intent-to-Treat Population: All participants who were randomized and received at least 1 dose of study drug and had an assessment at the specified timepoint.</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-140.83" spread="24.70"/>
                    <measurement group_id="O2" value="-176.66" spread="25.58"/>
                    <measurement group_id="O3" value="6.70" spread="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTSE Phase: ALP Levels</title>
        <description>Blood samples were evaluated for ALP levels.</description>
        <time_frame>LTSE Day 0 and LTSE Months 12, 24, 36, 48, and 60</time_frame>
        <population>All participants who received at least 1 dose of OCA in the open-label safety extension phase and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>LTSE OCA (DB OCA 5-10 mg)</title>
            <description>Participants previously receiving OCA 5-10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O2">
            <title>LTSE OCA (DB OCA 10 mg)</title>
            <description>Participants previously receiving OCA 10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O3">
            <title>LTSE OCA (DB Placebo)</title>
            <description>Participants previously receiving placebo in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O4">
            <title>Overall LTSE OCA</title>
            <description>After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>LTSE Phase: ALP Levels</title>
          <description>Blood samples were evaluated for ALP levels.</description>
          <population>All participants who received at least 1 dose of OCA in the open-label safety extension phase and had an assessment at the specified timepoint.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LTSE Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                    <count group_id="O2" value="63"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="192"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218.69" spread="100.328"/>
                    <measurement group_id="O2" value="191.24" spread="61.381"/>
                    <measurement group_id="O3" value="317.79" spread="139.666"/>
                    <measurement group_id="O4" value="243.75" spread="118.910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209.49" spread="93.157"/>
                    <measurement group_id="O2" value="198.68" spread="75.799"/>
                    <measurement group_id="O3" value="226.28" spread="105.404"/>
                    <measurement group_id="O4" value="211.47" spread="92.439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195.14" spread="80.361"/>
                    <measurement group_id="O2" value="194.57" spread="66.593"/>
                    <measurement group_id="O3" value="215.99" spread="83.469"/>
                    <measurement group_id="O4" value="201.47" spread="77.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.52" spread="68.019"/>
                    <measurement group_id="O2" value="214.66" spread="158.831"/>
                    <measurement group_id="O3" value="205.37" spread="65.206"/>
                    <measurement group_id="O4" value="208.27" spread="107.114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.75" spread="55.929"/>
                    <measurement group_id="O2" value="192.00" spread="59.761"/>
                    <measurement group_id="O3" value="198.70" spread="65.551"/>
                    <measurement group_id="O4" value="193.38" spread="60.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTSE Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="76"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.90" spread="97.475"/>
                    <measurement group_id="O2" value="191.37" spread="62.404"/>
                    <measurement group_id="O3" value="209.38" spread="82.240"/>
                    <measurement group_id="O4" value="200.94" spread="83.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LTSE Phase: ALP Change From DB Baseline</title>
        <description>Blood samples were evaluated for ALP levels. ALP Change From Baseline (ALP at LTSE Months 12, 24, 36, 48, and 60 - ALP at Baseline) is presented. DB baseline is the mean of all available evaluations prior to DB treatment.</description>
        <time_frame>DB Baseline, LTSE Months 12, 24, 36, 48, and 60</time_frame>
        <population>All participants who received at least 1 dose of OCA in the open-label safety extension phase and had an assessment at the specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>LTSE OCA (DB OCA 5-10 mg)</title>
            <description>Participants previously receiving OCA 5-10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O2">
            <title>LTSE OCA (DB OCA 10 mg)</title>
            <description>Participants previously receiving OCA 10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O3">
            <title>LTSE OCA (DB Placebo)</title>
            <description>Participants previously receiving placebo in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
          <group group_id="O4">
            <title>Overall LTSE OCA</title>
            <description>After completion of the 12-month DB phase all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
          </group>
        </group_list>
        <measure>
          <title>LTSE Phase: ALP Change From DB Baseline</title>
          <description>Blood samples were evaluated for ALP levels. ALP Change From Baseline (ALP at LTSE Months 12, 24, 36, 48, and 60 - ALP at Baseline) is presented. DB baseline is the mean of all available evaluations prior to DB treatment.</description>
          <population>All participants who received at least 1 dose of OCA in the open-label safety extension phase and had an assessment at the specified timepoint.</population>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="59"/>
                    <count group_id="O4" value="178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-106.63" spread="98.448"/>
                    <measurement group_id="O2" value="-104.39" spread="82.496"/>
                    <measurement group_id="O3" value="-104.36" spread="83.074"/>
                    <measurement group_id="O4" value="-105.13" spread="87.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="57"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-120.86" spread="96.614"/>
                    <measurement group_id="O2" value="-102.52" spread="79.413"/>
                    <measurement group_id="O3" value="-100.99" spread="87.181"/>
                    <measurement group_id="O4" value="-108.34" spread="87.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="56"/>
                    <count group_id="O2" value="55"/>
                    <count group_id="O3" value="49"/>
                    <count group_id="O4" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-100.98" spread="109.952"/>
                    <measurement group_id="O2" value="-84.65" spread="137.293"/>
                    <measurement group_id="O3" value="-112.73" spread="89.661"/>
                    <measurement group_id="O4" value="-98.96" spread="114.635"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="48"/>
                    <count group_id="O4" value="151"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-118.23" spread="101.527"/>
                    <measurement group_id="O2" value="-101.50" spread="91.335"/>
                    <measurement group_id="O3" value="-115.51" spread="106.774"/>
                    <measurement group_id="O4" value="-111.49" spread="99.433"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="21"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-118.99" spread="147.126"/>
                    <measurement group_id="O2" value="-117.49" spread="95.587"/>
                    <measurement group_id="O3" value="-119.52" spread="108.949"/>
                    <measurement group_id="O4" value="-118.74" spread="121.391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>DB Phase: Baseline up to 12 months (1 year). LTSE phase: Baseline (DB Month 12) up to 60 months (5 years).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DB 5-10 mg</title>
          <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remaining 6 months of the DB phase.</description>
        </group>
        <group group_id="E2">
          <title>DB OCA 10 mg</title>
          <description>OCA 10 mg for 12 months during the DB phase.</description>
        </group>
        <group group_id="E3">
          <title>DB Placebo</title>
          <description>Matching placebo for 12 months during the DB phase.</description>
        </group>
        <group group_id="E4">
          <title>LTSE OCA (DB OCA 5-10 mg)</title>
          <description>Participants previously receiving OCA 5 to 10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="E5">
          <title>LTSE OCA (DB 10 mg)</title>
          <description>Participants previously receiving OCA 10 mg in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="E6">
          <title>LTSE OCA (DB Placebo)</title>
          <description>Participants previously receiving placebo in the DB phase received OCA in the open-label LTSE phase for up to 5 years beginning at 5 mg, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
        <group group_id="E7">
          <title>Overall LTSE OCA</title>
          <description>After completion of the 12-month DB phase, all participants were offered the opportunity to enter an open-label LTSE for up to 5 years beginning at 5 mg OCA, and then the dose could be titrated up. Initially, participants were allowed to titrate to doses up to 25 mg, however, the maximum dose was then limited to 10 mg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="66"/>
                <counts group_id="E7" subjects_affected="69" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oesophageal varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Splenic artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Volvulus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hyperplastic cholecystopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Medical observation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Systemic sclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Colorectal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lip neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Renal atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.50</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="73"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="63"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="64"/>
                <counts group_id="E6" subjects_affected="64" subjects_at_risk="66"/>
                <counts group_id="E7" subjects_affected="187" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="25" subjects_affected="19" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="13" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="10" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="7" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="17" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" events="18" subjects_affected="9" subjects_at_risk="73"/>
                <counts group_id="E4" events="20" subjects_affected="14" subjects_at_risk="63"/>
                <counts group_id="E5" events="19" subjects_affected="13" subjects_at_risk="64"/>
                <counts group_id="E6" events="15" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E7" events="54" subjects_affected="37" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E4" events="15" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E5" events="17" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E6" events="26" subjects_affected="14" subjects_at_risk="66"/>
                <counts group_id="E7" events="58" subjects_affected="33" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="64"/>
                <counts group_id="E6" events="13" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E7" events="36" subjects_affected="31" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="12" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E7" events="29" subjects_affected="28" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="19" subjects_affected="17" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E4" events="12" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="25" subjects_affected="20" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="18" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="12" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="23" subjects_affected="20" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E4" events="15" subjects_affected="11" subjects_at_risk="63"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E7" events="32" subjects_affected="26" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="14" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Portal hypertensive gastropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="73"/>
                <counts group_id="E4" events="46" subjects_affected="24" subjects_at_risk="63"/>
                <counts group_id="E5" events="43" subjects_affected="24" subjects_at_risk="64"/>
                <counts group_id="E6" events="20" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E7" events="109" subjects_affected="63" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="15" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E5" events="12" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E7" events="37" subjects_affected="26" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="19" subjects_affected="16" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E7" events="15" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="14" subjects_affected="11" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="70"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E4" events="66" subjects_affected="23" subjects_at_risk="63"/>
                <counts group_id="E5" events="39" subjects_affected="23" subjects_at_risk="64"/>
                <counts group_id="E6" events="22" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E7" events="127" subjects_affected="57" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="15" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E4" events="31" subjects_affected="17" subjects_at_risk="63"/>
                <counts group_id="E5" events="27" subjects_affected="19" subjects_at_risk="64"/>
                <counts group_id="E6" events="23" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E7" events="81" subjects_affected="51" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E4" events="21" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E5" events="17" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E6" events="16" subjects_affected="11" subjects_at_risk="66"/>
                <counts group_id="E7" events="54" subjects_affected="34" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="17" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E5" events="17" subjects_affected="12" subjects_at_risk="64"/>
                <counts group_id="E6" events="17" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E7" events="51" subjects_affected="34" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="64"/>
                <counts group_id="E6" events="11" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E7" events="29" subjects_affected="24" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="10" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E7" events="24" subjects_affected="20" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="16" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="12" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="15" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="30" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="13" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="8" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="16" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="6" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="15" subjects_affected="6" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="7" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="21" subjects_affected="16" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="63"/>
                <counts group_id="E5" events="15" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E6" events="10" subjects_affected="10" subjects_at_risk="66"/>
                <counts group_id="E7" events="38" subjects_affected="31" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="17" subjects_affected="14" subjects_at_risk="63"/>
                <counts group_id="E5" events="23" subjects_affected="17" subjects_at_risk="64"/>
                <counts group_id="E6" events="18" subjects_affected="15" subjects_at_risk="66"/>
                <counts group_id="E7" events="58" subjects_affected="46" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="14" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E7" events="22" subjects_affected="21" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E7" events="25" subjects_affected="20" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="20" subjects_affected="15" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="16" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="14" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="13" subjects_affected="11" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="26" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E4" events="43" subjects_affected="20" subjects_at_risk="63"/>
                <counts group_id="E5" events="22" subjects_affected="15" subjects_at_risk="64"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="66"/>
                <counts group_id="E7" events="75" subjects_affected="44" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="9" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="18" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="64"/>
                <counts group_id="E6" events="11" subjects_affected="7" subjects_at_risk="66"/>
                <counts group_id="E7" events="24" subjects_affected="20" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="16" subjects_affected="13" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="7" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="7" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="8" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="11" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E4" events="23" subjects_affected="12" subjects_at_risk="63"/>
                <counts group_id="E5" events="16" subjects_affected="11" subjects_at_risk="64"/>
                <counts group_id="E6" events="16" subjects_affected="12" subjects_at_risk="66"/>
                <counts group_id="E7" events="55" subjects_affected="35" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="64"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="23" subjects_affected="18" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="8" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="7" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="93" subjects_affected="39" subjects_at_risk="70"/>
                <counts group_id="E2" events="99" subjects_affected="50" subjects_at_risk="73"/>
                <counts group_id="E3" events="49" subjects_affected="28" subjects_at_risk="73"/>
                <counts group_id="E4" events="249" subjects_affected="49" subjects_at_risk="63"/>
                <counts group_id="E5" events="198" subjects_affected="51" subjects_at_risk="64"/>
                <counts group_id="E6" events="180" subjects_affected="50" subjects_at_risk="66"/>
                <counts group_id="E7" events="627" subjects_affected="150" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="63"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="16" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="64"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="16" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="64"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="66"/>
                <counts group_id="E7" events="20" subjects_affected="14" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="5" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="7" subjects_affected="2" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="5" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="64"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E7" events="12" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="63"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="64"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="66"/>
                <counts group_id="E7" events="21" subjects_affected="19" subjects_at_risk="193"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="64"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="66"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="193"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45 day review period with the option to extend to an additional 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Intercept Pharmaceuticals, Inc.</organization>
      <phone>844-782-4278</phone>
      <email>medinfo@interceptpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

